Cargando…
Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo
BACKGROUND: Delivery of small interfering RNA (siRNA) to tumours remains a major obstacle for the development of RNA interference (RNAi)-based therapeutics. Following the promising pre-clinical and clinical results with the oncolytic herpes simplex virus (HSV) OncoVEX(GM-CSF), we aimed to express RN...
Autores principales: | Anesti, Anna-Maria, Simpson, Guy R, Price, Toby, Pandha, Hardev S, Coffin, Robert S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2944180/ https://www.ncbi.nlm.nih.gov/pubmed/20836854 http://dx.doi.org/10.1186/1471-2407-10-486 |
Ejemplares similares
-
Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus
por: Anesti, Anna-Maria, et al.
Publicado: (2008) -
Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo
por: Ghose, Jayeeta, et al.
Publicado: (2021) -
Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018) -
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
por: Simpson, Guy R, et al.
Publicado: (2016) -
Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)